Abstract
Vaccines are recognised as important tools for the prevention and control of diseases in fish. The regulatory requirements for registering veterinary vaccines have grown considerably over the last 50 years; nevertheless, they have contributed to a steady increase in the availability of vaccines of high quality with good safety profiles and proven efficacy against many diseases. In the EU, there are stringent requirements for vaccine manufacturers to comply with good manufacturing practice (GMP); consequently, the cost of vaccine production is high. Compared with vaccines for other animal species, the market for fish vaccines is limited in size; however, the cost in meeting the regulatory requirements is similar and the cost of development is equally expensive. Fortunately vaccines for use in small markets may take advantage of the Minor Use Minor Species Limited Market (MUMS) and limited market process for which the regulatory requirements are reduced where a successful application can be made for inclusion in the MUMS listings. Also, the field of animal ethics is constantly changing, leading to some reductions in the regulatory requirements for animal studies performed to generate safety, quality and efficacy data. The pharmaceutical industry needs to keep abreast of such changes and amend product development plans accordingly to remain competitive in the market.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Best practice guide for veterinary decentralized procedure (DCP) CMDv/BPG/002, Edition 05, 7 November 2013
Commission Directive 2009/9/EC of February 2009 amending Directive 2001/82/EC
Commission Directive 92/18/EC, Title II, Requirements for immunological veterinary medicinal products
European Pharmacopoeia (Ph Eur) monograph 0062: Vaccines for Veterinary Use
General requirements for the production and control of live Mammalian bacterial and viral vaccines for veterinary use WC50004652 Vol. 7BIm1a
Guideline on data requirements for IVMPs intended for minor use or minor species/limited markets. EMA/CVMP/IWP/123243/200
Guideline on requirements for the production and control of immunological veterinary medicinal products EMA/CVMP/IWP/206555/2010, effective 1 January 2013
Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines, EMA/CVMP/IWP/314550/2010, effective 1 May 2012
Note for guidance, statistical principles for veterinary clinical trials EMA/CVMP/EWP/81976/2010
Note for guidance, field trails with veterinary vaccines EMA/CVMP/852/99
Note for guidance: duration of protection achieved by veterinary vaccines, EMA/CVMP/682/99-FIANAL
Notice to applicants eudralex, Volume 6A, European commission. http://ec.europa.eu/health/documents/eudralex/vol-6/index_en.htm
OECD principles on good laboratory practice
Ph Eur 01/2005:50103, chapter 5.1.3 Efficacy of antimicrobial preservatives
QRD templates, EMA website – Veterinary Regulatory. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000253.jsp&mid=WC0b01ac058008af8a
Requirements for the production and control of inactivated Mammalian bacterial and viral vaccines for veterinary use (1992) WC50004651 Vol. 7BIm2a III/3181/91
Revised position paper on indications for veterinary vaccines, EMA/CVMP/042/97-Rev.1-FINAL
Setting up GCP trials in fish, by Janet Stone and Alastair McLean, Ch 5, veterinary clinical trials from concept to completion edited by Nigel Dent and Ramzan Visanji ISBN 1-57491-121-X
Table of Extraneous Agents to be Tested for in relation to the General and Species Specific Guidelines on Production and Control of Mammalian Veterinary Vaccines Vol 7BI10a, (A draft replacement, for this guideline, EMA/CVMP/IWP/105112/2011, is currently under consultation)
VICH GL 2: Validation of analytical procedures: methodology
VICH GL1: Guideline on validation of analytical procedures: definition and terminology
VICH GL41 Target animal safety: examination of live veterinary vaccines in target animals for absence of reversion to virulence
VICH GL44 Guideline on target animal safety for veterinary live and inactivated vaccines EMEA/CVMP/VICH/359665/2005, effective July 2007
VICH GL9, (GCP) Guideline on Good Clinical Practices (CVMP/VICH/595/98-FINAL)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Basel
About this chapter
Cite this chapter
Cowan, G., Smith, P., Christofilogiannis, P. (2016). Fish Vaccines: The Regulatory Process and Requirements from the Laboratory Bench to a Final Commercial Product, Including Field Trials. In: Adams, A. (eds) Fish Vaccines. Birkhäuser Advances in Infectious Diseases. Springer, Basel. https://doi.org/10.1007/978-3-0348-0980-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-0348-0980-1_5
Published:
Publisher Name: Springer, Basel
Print ISBN: 978-3-0348-0978-8
Online ISBN: 978-3-0348-0980-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)